Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Medical sciences and Public health

March 31, 2023; Zurich, Switzerland: IV International Scientific and Practical Conference «GRUNDLAGEN DER MODERNEN WISSENSCHAFTLICHEN FORSCHUNG»


MODERN ASPECTS OF TREATMENT OF WOMEN WITH POLYCYSTIC OVARY SYNDROME


DOI
https://doi.org/10.36074/logos-31.03.2023.50
Published
14.04.2023

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common neuroendocrine syndromes of reproductive age, affecting up to 20% of women in this age group. This condition is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovary morphology. In the pathophysiology of PCOS, there is a violation of the circadian rhythm of GnRH secretion, which increases the release of LH and decreases FSH. The latter is necessary for the synthesis of aromatases, which convert androgens into estrogens [7].

Another pathophysiological link in the development of PCOS is insulin resistance.

Androgen hypersecretion increases the level of insulin resistance, and the hyperinsulinemia that develops due to insulin resistance further increases androgen secretion and induces the production of sex hormone-binding globulin (SHBG) in the liver, thereby increasing the concentration of free testosterone in the blood and even more aggravates disorders associated with hyperandrogenism.

In 2003, a consensus of experts at a joint ESHRE/ASRM symposium in Rotterdam adopted diagnostic criteria (remaining relevant to this day), which include a triad of signs: oligoovulation or anovulation; hyperandrogenism (clinical and/or biochemical manifestations); polycystic ovaries detected during ultrasound; diagnosed on the basis of at least two of the following signs [7].

Patients may have different manifestations of this triad depending on the disease phenotype, patient age, and lifestyle. Therefore, treatment strategies are symptomatic and depend on desired goals and clinical preferences.

References

  1. Abeer M. Rababa’h, Bayan R. Matani, and Alaa Yehya . (2022) An update of polycystic ovary syndrome: causes and therapeutics options. Heliyon, 8(10): e11010. doi: 10.1016/j.heliyon.2022.e11010
  2. Decio Armanini, Marco Boscaro, Luciana Bordin, and Chiara Sabbadin. (2022) Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci, 23(8): 4110. doi: 10.3390/ijms23084110
  3. Jiaqi Zhang, Chuan Xing, Xiangyi Cheng, and Bing He. (2022) Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. Front Endocrinol (Lausanne),13:1003238. doi: 10.3389/fendo.2022.1003238
  4. Lila Vyas, Anagha Pai Raiturker, Shilpi Sud, Poonam Goyyal, Mahesh Abhyankar, Santosh Revankar, and Silki Walia. (2022) Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol. Bioinformation.2022;18(2):103–110. doi: 10.6026/97320630018103
  5. Semenyna H. B., Fartushok T.V., Starykovych A.V. (2021) Relationship between obesity and the risk of comorbidities diseases. Global Issues in Academic Research, 65-71.
  6. Semenyna H.B., Shatylovych K.L.,Fartushok T.V., Komissarova O., Yurchyshyn O.M. (2020) A new approach to the combination therapy of polycystic ovary syndrome. World of Medicine and Biology, 2(72): 125-128. DOI 10.26724/2079-8334-2020-2-72-125-129.
  7. Semenyna HB. Neuroendocrine syndromes in gynecology. 2011; ISBN 978-966-8792-69-4
  8. Shanshan Mei, Jie Ding, Kaili Wang, Zhexin Ni and Jin Yu. (2022) Mediterranean Diet Combined With a Low-Carbohydrate Dietary Pattern in the Treatment of Overweight Polycystic Ovary Syndrome Patients. Front Nutr, 9: 876620. doi: 10.3389/fnut.2022.876620
  9. Yalan Xu and Jie Qiao. (2022) Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS):A Review of Literature. J Healthcare Engineering, ID 9240569:13. doi: 10.1155/2022/9240569
  10. Yishu Wang, Peter Leung, Rong Li, Yanting Wu, Hefeng Huang. (2022) Editorial: Polycystic ovary syndrome (PCOS): Mechanism and management. Front Endocrinol (Lausanne), 7;13:1030353. doi:10.3389/fendo.2022.1030353.
  11. Yuanyuan Gu, Guannan Zhou, Fangyue Zhou, Qiongwei Wu, Chengbin Ma, Yi Zhang, Jingxin Ding,and Keqin Hua . (2022) Life Modifications and PCOS: Old Story But New Tales. Front Endocrinol (Lausanne),13:808898. doi: 10.3389/fendo.2022.808898.